Tools   Select Another Resource Report Type

http://www.neurotechindustry.org/

The Neurotechnology Industry Organization (NIO) is a non-profit trade association that represents companies involved in neuroscience (neuropharmaceuticals, cell-based therapeutics, neurodevices and neurodiagnostics), academic neuroscience research centers, and brain-illness advocacy groups across the United States and throughout the world. NIO was formed to provide a unified voice for the commerical neuroscience community. NIO advocates for its member organizations on a range of issues related to neurotechnology research and business development including favorable changes in the tax code, intellectual property issues, neuroethics, public policy, reimbursement and patient advocacy. Thank you for taking the time to read this brief introduction to the Neurotechnology Industry Organization (NIO), the recently formed trade association representing companies involved in neuroscience (drugs, devices and diagnostics), brain research centers, patient advocacy groups, and research foundations worldwide. NIO was founded in August 2006 and has attracted over 80 member organizations. NIO''s mission is to accelerate treatments and cures for brain and nervous system illnesses by: * Advocating neurotech''s position to government and regulatory officials * Promoting the industry''s progress and contributions to quality of life * Providing industry development services for our members NIO is spearheading several innovative programs that will benefit your company including: National Neurotechnology Initiative - a new $200M/year Federal initiative aimed at accelerating translational neuroscience innovation and improving the effectiveness of the FDA review process for neuroscience drugs, devices and diagnostics NIO/FDA private-public working group - an initiative to work collaboratively with the FDA to improve the efficiency of the evaluation process for neuroscience products and to increase communication and clarity during the regulatory process Partnering, investment and policy events - networking events with other members of the global commercial neuroscience community at events such as the annual public policy tour in March in Washington D.C. and the Neurotech investing and partnering conference in Spring National Visibility - NIO actively outreaches to global media outlets to encourage coverage of Neurotech that will foster great investor, policymaker and consumer interest. As a member of NIO you will enjoy the following benefits: * Influence in the industry''s overall development agenda * Access to key opinion leaders in Congress, regulatory agencies, media * Participation in FDA and CMS working groups, stakeholder meetings * Expanded networking at neurotech investing and partnering events throughout the year * Participation in neuroscience education awareness initiatives, public awareness campaigns * Industry leadership through participation in driving innovative legislation, new projects NIO''s programs increase awareness of commercial neuroscience products, reduce barriers to innovation, support industry growth and will benefit your company and industry. I hope that you will consider joining NIO in support of our mission to give the brain a voice..

Proper citation: Neurotechnology Industry Organization (RRID:SCR_006556) Copy   

•   Source: SciCrunch Registry

http://1mind4research.org/

One Mind for Research''s plan to work smarter and share resources through public and private partnerships has the power to help us make more progress on every brain disorder from schizophrenia to traumatic brain injury. In the process, we will increase the investment in research by $1.5 billion each year for the next 10 years. And achieve a minimum 10% reduction in the cost of brain disease per year. This is how neurological cures that once seemed beyond our reach begin to take shape. When we''re all of one mind working toward the same goal, anything can be accomplished. $8 billion a year is spent on brain research, but the minimum cost of brain disease is one hundred times that. Yet amazingly, unlocking the mysteries of the human brain has less to do with resources than it does their coordination. Because though there is science, it exists in many different silos. There has never been a single organization that brings together the science, technology, financial resources and knowledge required to create an unprecedented understanding of brain disease. Until now. The One Mind for Research Forum began on May 23, 2011 and over the course of 2 days, the best and brightest from around the world gathered as part of a national collaboration of research universities, scientists, and the National Institutes of Health (NIH) Directors as they imagined an ambitious 10-year plan for neuroscience research. One Mind believes that new treatments and cures for neurological and psychiatric diseases that afflict one in three Americans, from children with autism to senior citizens with Alzheimer''s disease, are all within reach.

Proper citation: One Mind for Research (RRID:SCR_006711) Copy   

•   Source: SciCrunch Registry

http://www.neurodevnet.ca/

NeuroDevNet, a Canadian Network of Centres of Excellence (NCE), is dedicated to helping children overcome neurodevelopmental disorders. Network investigators seek to understand the causes of neurological deficits, and to transfer this knowledge to health care professionals, policy makers, and communities of interest. NeuroDevNet works with its partners in academia, the community, not-for-profit sector, industry, and government, and across traditional disciplinary boundaries and sectors, to ensure generated knowledge is translated into tangible diagnostic, preventative, therapeutic, social, economic, and health benefits for all. NeuroDevNet supports transformative research, provides training to build a new generation of Canadian researchers, strengthens communities with the right tools and information, and translates research findings into early diagnostic, preventative, and therapeutic strategies for children with neurological disorders to live healthier lives. Currently, the network''s research focuses on autism spectrum disorder, cerebral palsy, and fetal alcohol spectrum disorder. These demonstration projects are supported by NeuroDevNet''s central infrastructure and cores, including Neuroethics, Neuroinformatics, and Knowledge Translation.

Proper citation: NeuroDevNet (RRID:SCR_004925) Copy   

•   Source: SciCrunch Registry

http://nimh-repository.rti.org/

A program that synthesizes, purifies, and distributes otherwise unavailable essential compounds to stimulate basic and clinical research in psychopharmacology relevant to mental health in areas such as the molecular pharmacology and signaling of CNS receptors, longitudinal studies to evaluate the molecular, biochemical, and behavioral actions of psychoactive compounds, and functional brain imaging in both primates and humans. WHAT IS AVAILABLE: * Ligands for CNS receptors, radiolabeled compounds for autoradiography and neuroimaging, biochemical markers, drug analogs and metabolites, and reference standards * Synthesis (including GMP) of promising compounds for mental health research, including preclinical toxicology and safety studies, especially compounds for PET neuroimaging * A listing of currently available NIMH CSDSP compounds is available online at www.nimh-repository.rti.org. RTI International scientists can provide investigators with technical assistance and additional information about the compounds on request. Data sheets containing purity, storage, and handling information are supplied with all NIMH CSDSP compounds. WHO IS ELIGIBLE: Investigators involved in basic or clinical research relevant to mental health are eligible to submit requests. To learn more about current NIMH research areas, please visit the NIMH website at www.nimh.nih.gov. NIMH CSDSP compounds are free to qualified academic investigators, but payment may be required from nonacademic requestors. Investigators interested in obtaining radiolabeled compounds but uncertain about what type of label or specific activity would work best for them may obtain help by communicating with the technical contacts listed on the website.

Proper citation: NIMH Chemical Synthesis and Drug Supply Program (RRID:SCR_004921) Copy   

•   Source: SciCrunch Registry

http://www.nitrc.org/projects/namicdtifiber/

Project hosting binary packaged distributions, scripts, example datasets, and corresponding results of analysis using their UNC/Utah NAMIC DTI Fiber Analysis Framework. This project can be seens as a master project encompassing several current NITRC projects into a coherent set. Their workflow utilizes tools already available on NITRC including: * DTIPrep * DTIAtlasBuilder * FiberViewerLight * DTIAtlasFiberAnalyzer * FADTTS

Proper citation: UNC/Utah NAMIC DTI Fiber Analysis Framework (RRID:SCR_009615) Copy   

•   Source: SciCrunch Registry

http://www.floridaaquaculture.com

This web site is your introduction to the world of Florida Aquaculture. It represents a compilation of information about a division in the Florida Department of Agriculture and Consumer Services-the Division of Aquaculture. The Division plays a key role in the regulation of aquaculture facilities and shellfish processing plants, is responsible for opening/closing of shellfish harvesting waters to protect human health, ensures the continued productivity of oyster reefs through a restoration program and issues leases of submerged state lands for aquaculture. The creation of this division is unprecedented for a state agriculture department. Florida''s Division of Aquaculture is one-of-a-kind and serves a unique industry like no other in the United States. Please browse this site and learn more about Florida Aquaculture. I welcome your comments on the topics contained in this web site.

Proper citation: Division of Aquaculture (RRID:SCR_008484) Copy   

•   Source: SciCrunch Registry

http://www.dtu.ox.ac.uk

It was founded in 1985 by Professor Rury Holman, specialises in performing diabetes-related national and multinational mega trials in partnership with the NHS, NIH, MRC, BHF, DUK, academic institutions and industry. The DTU also undertakes major modelling and statistical programmes to utilise fully the data available from its many studies, with a particular emphasis on modelling diabetes and cardiovascular disease processes. Current studies include 4-T, ACE, TECOS and UKPDS~Post Study Monitoring. Sponsor. Funded by the UK National Institute for Health Research

Proper citation: DTU (RRID:SCR_008481) Copy   

•   Source: SciCrunch Registry

http://www.mitre.org/

The MITRE Corporation is a not-for-profit organization chartered to work in the public interest. As a national resource, we apply our expertise in systems engineering, information technology, operational concepts, and enterprise modernization to address our sponsors'' critical needs. MITRE manages Federally Funded Research and Development Centers (FFRDCs): one for the Department of Defense (known as the DoD Command, Control, Communications and Intelligence FFRDC), one for the Federal Aviation Administration (the Center for Advanced Aviation System Development), one for the Internal Revenue Service and U.S. Department of Veterans Affairs (the Center for Enterprise Modernization), and one for the Department of Homeland Security (the Homeland Security Systems Engineering and Development Institute). We believe that each FFRDC benefits from being part of an independent, not-for-profit company managing multiple FFRDCs. MITRE also has its own independent research and development program that explores new technologies and new uses of technologies to solve our sponsors'' problems in the near-term and in the future. MITRE has 7,000 scientists, engineers and support specialists65 percent of whom have Masters or Ph.D. degrees. Staff members work on hundreds of different projects across the company, demanding a high level of technical, operational, and domain knowledge. The MITRE Corporation has two principal locations: Bedford, Massachusetts, and McLean, Virginia. MITRE also has additional sites across the country and around the world.

Proper citation: MITRE (RRID:SCR_010690) Copy   

•   Source: SciCrunch Registry

http://www.tcgls.com/

Leading contract research and manufacturing services company in the area of drug discovery and development.

Proper citation: TCG Life Sciences (RRID:SCR_010571) Copy   

•   Source: SciCrunch Registry

http://www.medscape.com/public/iphone

Free medical app for comprising a drug reference, drug interaction checker, disease and condition reference, procedures and protocols and specialty-focused Medical News * Drug Reference: Search prescribing and safety information for over 8,000 brand, generic and OTC drugs, herbals and supplements * Drug Interaction Checker: Check mild interactions to serious contraindications for any combination of drugs, herbals and supplements * Disease & Condition Reference: Review the latest in-depth clinical information for 4,000+ diseases and conditions (enhanced with images and videos) *Procedures & Protocols: Follow detailed stepbystep instructions for 600+ clinical procedures, including 80+ widely used Tables & Protocols * Specialty-focused Medical News: Read in-depth medical news articles daily in 30 specialty areas

Proper citation: Medscape App for iPhone and iPod touch (RRID:SCR_010610) Copy   

•   Source: SciCrunch Registry

http://dererumnatura.us/

His research interests cover many different questions in population genetics and molecular evolution. He considers himself an evolutionary geneticist, with strengths in computational biology and stochastic models. He has worked on frequency-dependent selection models, spatial genetic models, indel evolution models, sequence alignment, and phylogenetic models. His current research involves estimating indel rates and length distributions, applying population genetic models to phylogeny reconstruction, and finding de novo mutations and SNPs from next-gen sequencing of human genomes. In addition to running De Rerum Natura, Reed also manages the largest group blog on evolution, The Pandas Thumb. In addition he develops plugins and hacks for the Movable Type blogging software. He is an expert on dispatching MT under FastCGI and Lighttpd, as well as integrating it with jQuery. He was editor and designer of The Open Laboratory: The Best Science Writing on Blogs 2007. He is co-creator of Prof. Steve Steve. Partners. Movable Type Site Meter Melody Lulu

Proper citation: De Rerum Natura (RRID:SCR_008475) Copy   

•   Source: SciCrunch Registry

https://research.uga.edu/core-facilities/

University of Georgia Core Facilities provide equipment and services to researchers at UGA, other universities, government agencies, nonprofit organizations and industry. These facilities make use of highly specialized scientific equipment, diagnostic tools, adaptable prototyping processes and mechanical production shops.

Proper citation: University of Georgia Labs and Facilities (RRID:SCR_011033) Copy   

•   Source: SciCrunch Registry

http://informedmedicaldecisions.org/

Mission The Foundation for Informed Medical Decision Making is a non-profit organization dedicated to assuring that people understand their choices and have the information they need to make sound decisions affecting their health and well being. To accomplish our mission: We promote understanding and adoption of informed medical decision-making. We organize and frame medical evidence in an unbiased manner to help people evaluate their options, particularly in instances where differences in individual preferences and perspectives are likely to affect personal choice. We sponsor research to expand knowledge of how to improve decision quality in health care. Medical Evidence The science of medical care is advancing at a rate that makes the delivery of quality patient-focused care an enormous challenge. New information about disease biology and genetics, rapid development of new tests and treatments, and the shift in disease from largely acute to largely chronic are all important contributing factors. Patient Perspective Medical research on practice variation indicates that patient perspectives are often less important in treatment decisions than factors having little to do with patients or their illnesses, such as geography, economics or supplier-induced demands. The Foundation brings the patient perspective into focus by interviewing real patients who can talk about the choices they made and why. Without the perspective of the patient, we cannot achieve a quality medical decision. Informed Medical Decisions The Foundation believes that it is the convergence of the two concepts: medical evidence and patient perspectives that create a truly informed decision in medical care. Funding The Foundation has worked in a unique partnership with Health Dialog since 1997. Health Dialog delivers patient support services to employers and health plans that are committed to providing excellence to their members or employees. As of July 2006, Health Dialog served seventeen million people through its contracts with healthcare insurers and corporations. Access to the Foundation''s decision support materials is a key benefit that Health Dialog''s clients receive. Health Dialog produces the Foundation''s new programs and distributes decision support materials and services to patients. A portion of Health Dialog''s revenue goes to the Foundation in the form of royalties to support the development of new decision support materials and research on how best to support patient decisions. The Foundation does not accept funding from any source that has a financial interest in any particular approach to medical testing or treatment. Foundation employees and clinical content experts do not accept support from companies that commercially market any kind of treatment or device that might be relevant to a program.

Proper citation: Foundation for Informed Medical Decision Making (RRID:SCR_008509) Copy   

•   Source: SciCrunch Registry

http://www.kew.org/index.htm

Throughout its history, the Royal Botanic Gardens, Kew has made important contributions to increasing the understanding of the plant kingdom with many benefits for mankind. Today it is still first and foremost a scientific institution. With its collections of living and preserved plants, of plant products and botanical information, it forms an encyclopaedia of knowledge about the plant kingdom.

Proper citation: Royal Botanic Gardens Kew (RRID:SCR_010543) Copy   

•   Source: SciCrunch Registry

http://tikus.gsf.de

THIS RESOURCE IS NO LONGER IN SERVICE, documented on October 23, 2014. Consortium that generated a reference library of gene trap sequence tags (GTST) from insertional mutations generated in mouse embryonic stem (ES) cells. The gene trap database represents a repository of sequences produced in a large scale gene trap screen in mouse ES cells using various gene trapping vectors which are delivered either by electroporation or retroviral infections. A type of retroviral gene trap vector has been developed that can induce conditional mutations in most genes expressed in mouse embryonic stem (ES) cells. The vectors rely on directional site-specific recombination systems that can repair and re-induce gene trap mutations when activated in succession. After the gene traps are inserted into the mouse genome, genetic mutations can be produced at a particular time and place in somatic cells. In addition to their conditional features, the vectors create multipurpose alleles amenable to a wide range of post-insertional modifications. Here they have used these directional recombination vectors to assemble the largest library of ES cell lines with conditional mutations in single genes yet assembled, presently totaling 1,000 unique genes. The trapped ES cell lines, which can be ordered from the German Gene Trap Consortium, are freely available to the scientific community.

Proper citation: German Gene Trap Consortium (RRID:SCR_008532) Copy   

•   Source: SciCrunch Registry

https://www.unr.edu/ncar/infrastructure

Nevada Center for Applied Research coordinates access to Shared Research Facilities extensive resource of labs with cutting edge research and development equipment available to internal University community and external clients from industry, government, research organizations and other institutions.In addition to services and instrumentation, we offer support from highly experienced staff with expertise in designing and conducting experiments and analyzing data. Many facilities can also provide training and education upon request.

Proper citation: University of Nevada Reno Labs and Facilities (RRID:SCR_011008) Copy   

•   Source: SciCrunch Registry

http://www.emqn.org

Welcome to the EMQN website. EMQN is a not-for-profit organisation promoting quality in molecular genetic testing through the provision of external quality assessment (proficiency testing schemes) and the organisation of best practice meetings and publication of guidelines. The European Molecular Genetics Quality Network (EMQN) started in October 1998 after a successful pilot trial. From January 1999 to March 2002, the network was supported by a grant from the European Commission under the Standards Measurement and Testing Programme (contract number SMT4-CT98-7515). From April 2002, the network is supported by subscriptions from it users. External Quality Assessment (EQA): There are 26 EQA schemes being offered in 2010. To participate you must be a registered member of the network. For more information on EQA schemes, click the link here. Best Practice: EMQN is actively promoting ''best practice'' meetings on individual diseases. To assist in this process, EMQN will be organising best practice meetings. To participate you must be a registered member of the network. Following the meeting, draft best practice guidelines are produced and publised on this and other related websites, for example, the web site of the UK Clinical Molecular Genetics Society (CMGS). To find out more about best practice click here. Administration: The EMQN is based at the National Genetics Reference Laboratory (Manchester), St Mary''s Hospital, Manchester, The United Kingdom. The Network is co-ordinated and administered by Dr''s Rob Elles and Simon Patton. A management group is responsible for the activities and direction of the network. National partners in different countries help to disseminate information about the network. Quality Policy The EMQN provides a comprehensive range of quality assurance programs for molecular genetics to laboratories and industry worldwide. The European Molecular Genetics Quality Network (EMQN) is committed to helping ensure diagnostic molecular genetic laboratory test results are accurate, reliable and comparable wherever they are produced. The EMQN will provide a high quality and timely service which takes into account the needs and requirements of its users. Objectives To help to raise and maintain the standards of diagnostic clinical molecular genetic testing. To undertake and promote educational activities. To be a leading authority in quality assurance . To design and provide the best possible materials and data management. To design and provide quality reports that are timely and valid. To provide professional support and consultation. To develop new programs as required. To participate in peer review. To strive for continual improvement of the quality system. Sponsor. the network was supported by a grant from the European Commission under the Standards Measurement and Testing Programme (contract number SMT4-CT98-7515

Proper citation: European Molecular Quality Network (RRID:SCR_008494) Copy   

•   Source: SciCrunch Registry

http://narayanahospitals.com/cellsofhope/

Narayana Hrudayalaya Tissue Bank and Stem Cell Research Center (NHTB-SCRC) is a joint venture between Rotary Bangalore Health City (RBHC) and Narayana Hrudayalaya. Our mission is to create awareness on Cord Blood Banking among the masses. Our vision is to make sure that every pregnant mother in India is able to afford to bank her child''s cord blood and cord tissue in a novel form of ������??Biological Insurance������??. The center would also assist in research and development of newer stem cell therapies. These goals are met while ensuring patient safety and well being by maintaining compliance with ICMR guidelines, Good Manufacturing Practice (GMP) guidelines, strict confidentiality and adherence to ethical standards. The private cord blood bank would store cord-blood and cord tissue derived stem cells for the exclusive use of clients who would pay for the cryo-storage, for a period of 21 years. These samples would be used for the child or its siblings anytime in the future, for therapy of various medical conditions. The public cord blood bank would enable us to collect cord blood from delivery and birthing centers, process these specimens, type their HLA signature and store them in ultra-low temperature conditions for use on prospective recipients. These recipients would have to be matched against their HLA signature with the stored stem cell concentrate. Patients with a disease treatable by stem cell therapy would have to have their HLA type known and they approach us for treatment. Such patients would be matched against our library of samples to identify a suitable match which would then be issued at a nominal cost. The cost of therapy would however be separate and informed to the patient before embarking on the treatment.

Proper citation: Narayana Hrudayalaya Tissue Bank and Stem Cell Research Center (RRID:SCR_010680) Copy   

•   Source: SciCrunch Registry

http://www.zymogenetics.com.

Founded in 1981, ZymoGenetics is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins. ZymoGenetics is publicly traded (NASDAQ: ZGEN) and headquartered in Seattle, Washington in the historic Seattle City Light Steam Plant building. Our mission is to create novel protein drugs that will significantly help patients fight their diseases. We have contributed to the discovery or development of six recombinant protein products now marketed by other companies. Current programs target viral infection, cancer, inflammatory diseases and bleeding. Our first internally developed product, RECOTHROM Thrombin, topical (Recombinant), was approved by the U.S. Food and Drug Administration (FDA) on January 17, 2008 for use as a topical hemostat to control moderate bleeding during surgical procedures and is now marketed in the United States. We have a promising pipeline of novel therapeutics, which we are developing on our own or in collaboration with partners.

Proper citation: Zymo Genetics (RRID:SCR_008602) Copy   

•   Source: SciCrunch Registry

http://repeatmasker.genome.washington.edu

Welcome to the Department of Genome Sciences, which began in September 2001 by the fusion of the Departments of Genetics and Molecular Biotechnology. Our goal is to address leading edge questions in biology and medicine by developing and applying genetic, genomic and computational approaches that take advantage of genomic information now available for humans, model organisms and a host of other species. Our faculty study a broad range of topics, including the genetics of E. coli, yeast, C. elegans, Drosophila, and mouse; human and medical genetics; mathematical, statistical and computer methods for analyzing genomes, and theoretical and evolutionary genetics; and genome-wide studies by such approaches as sequencing, transcriptional and translational analysis, polymorphism detection and identification of protein interactions. Our chair, Dr. Robert Waterston, joined the department in January 2003. Our department includes both faculty with primary appointments in Genome Sciences, as well as adjuncts in other departments and Seattle institutions. Nine faculty are members of the National Academy of Sciences, including 2001 Nobel Prize winner Dr. Lee Hartwell, who conducted much of his groundbreaking work in the Department of Genetics. Five training faculty are Howard Hughes Medical Institute Investigators. Graduate research in the Department leads to a Ph.D. in Genome Sciences and students may also choose to participate in the Computational Molecular Biology or Molecular Medicine programs. Our department has around 55 - 60 graduate students at any given time and has moved into the new William H. Foege Building.

Proper citation: UW Genome Sciences (RRID:SCR_008562) Copy   

•   Source: SciCrunch Registry